Total Payments
$28,733
2023 Payments
$14,000
Companies
6
Transactions
21
Payment Breakdown by Category
Other$14,000 (48.7%)
Consulting$11,600 (40.4%)
Research$2,393 (8.3%)
Travel$475.78 (1.7%)
Food & Beverage$239.77 (0.8%)
Education$25.00 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Honoraria | $14,000 | 2 | 48.7% |
| Consulting Fee | $11,600 | 3 | 40.4% |
| Unspecified | $2,393 | 7 | 8.3% |
| Travel and Lodging | $475.78 | 2 | 1.7% |
| Food and Beverage | $239.77 | 5 | 0.8% |
| Education | $25.00 | 2 | 0.1% |
Payments by Type
General
$26,341
14 transactions
Research
$2,393
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| USWM, LLC | $14,000 | 2 | $0 (2023) |
| EUSA Pharma (US) LLC | $12,170 | 8 | $0 (2021) |
| F. Hoffmann-La Roche AG | $2,257 | 6 | $0 (2022) |
| Eli Lilly and Company | $136.00 | 1 | $0 (2021) |
| United Therapeutics Corporation | $97.12 | 3 | $0 (2022) |
| Hoffmann-La Roche Limited | $73.82 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $14,000 | 2 | USWM, LLC ($14,000) |
| 2022 | $284.80 | 2 | F. Hoffmann-La Roche AG ($212.68) |
| 2021 | $5,136 | 2 | EUSA Pharma (US) LLC ($5,000) |
| 2020 | $5,069 | 8 | EUSA Pharma (US) LLC ($3,000) |
| 2019 | $4,243 | 7 | EUSA Pharma (US) LLC ($4,170) |
All Payment Transactions
21 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/25/2023 | USWM, LLC | — | Honoraria | Cash or cash equivalent | $7,000.00 | General |
| 08/25/2023 | USWM, LLC | — | Honoraria | Cash or cash equivalent | $7,000.00 | General |
| 06/06/2022 | United Therapeutics Corporation | UNITUXIN (Drug) | Food and Beverage | In-kind items and services | $72.12 | General |
| Category: Oncology | ||||||
| 03/31/2022 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $212.68 | Research |
| Study: A PHASE 11B, OPEN-LABEL, DOSE-ESCALATION AND EXPANSION STUDY OF ENTRECTINIB RXDX-101 IN CHILDREN AND ADOLESCENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS AND PRIMARY CNS TUMORS, WITH OR WITHOUT TRK, ROS1, OR ALK FUSIONS | ||||||
| 04/30/2021 | EUSA Pharma (US) LLC | Sylvant (Drug) | Consulting Fee | Cash or cash equivalent | $5,000.00 | General |
| Category: Hematology | ||||||
| 03/25/2021 | Eli Lilly and Company | — | — | In-kind items and services | $136.00 | Research |
| Study: A RANDOMIZED, OPEN-LABEL PHASE 1/2 STUDY EVALUATING RAMUCIRUMAB IN PEDIATRIC PATIENTS AND YOUNG ADULTS WITH RELAPSED, RECURRENT, OR REFRACTORY DESMOPLASTIC SMALL ROUND CELL TUMOR | ||||||
| 12/31/2020 | F. Hoffmann-La Roche AG | ROZLYTREK (Biological) | — | In-kind items and services | $343.46 | Research |
| Study: Open Label Dose Escalation and Expansion Study of Entrectinib RXDX 101 in Children • Category: BioOncology | ||||||
| 09/28/2020 | United Therapeutics Corporation | UNITUXIN (Drug) | Education | In-kind items and services | $12.50 | General |
| Category: Oncology | ||||||
| 09/28/2020 | United Therapeutics Corporation | UNITUXIN (Drug) | Education | In-kind items and services | $12.50 | General |
| Category: Oncology | ||||||
| 06/30/2020 | F. Hoffmann-La Roche AG | ROZLYTREK (Biological) | — | In-kind items and services | $981.39 | Research |
| Study: A Phase 11b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib RXDX-101 in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors, with or without TRK, ROS1, or ALK Fusions • Category: BioOncology | ||||||
| 06/30/2020 | F. Hoffmann-La Roche AG | ROZLYTREK (Biological) | — | In-kind items and services | $359.19 | Research |
| Study: A Phase 11b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib RXDX-101 in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors, with or without TRK, ROS1, or ALK Fusions • Category: BioOncology | ||||||
| 05/07/2020 | EUSA Pharma (US) LLC | SYLVANT (Drug) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: Hematology | ||||||
| 03/31/2020 | F. Hoffmann-La Roche AG | ROZLYTREK (Biological) | — | In-kind items and services | $181.55 | Research |
| Study: A Phase 11b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib RXDX-101 in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors, with or without TRK, ROS1, or ALK Fusions • Category: BioOncology | ||||||
| 03/31/2020 | F. Hoffmann-La Roche AG | ROZLYTREK (Biological) | — | In-kind items and services | $178.58 | Research |
| Study: A Phase 11b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib RXDX-101 in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors, with or without TRK, ROS1, or ALK Fusions • Category: BioOncology | ||||||
| 12/06/2019 | EUSA Pharma (US) LLC | Sylvant (Biological) | Consulting Fee | Cash or cash equivalent | $3,600.00 | General |
| Category: Pediatric Oncology | ||||||
| 12/06/2019 | EUSA Pharma (US) LLC | Sylvant (Biological) | Travel and Lodging | Cash or cash equivalent | $329.30 | General |
| Category: Pediatric Oncology | ||||||
| 12/06/2019 | EUSA Pharma (US) LLC | Sylvant (Biological) | Travel and Lodging | Cash or cash equivalent | $146.48 | General |
| Category: Pediatric Oncology | ||||||
| 12/06/2019 | EUSA Pharma (US) LLC | Sylvant (Biological) | Food and Beverage | Cash or cash equivalent | $48.60 | General |
| Category: Pediatric Oncology | ||||||
| 12/06/2019 | EUSA Pharma (US) LLC | Sylvant (Biological) | Food and Beverage | Cash or cash equivalent | $23.88 | General |
| Category: Pediatric Oncology | ||||||
| 12/06/2019 | EUSA Pharma (US) LLC | Sylvant (Biological) | Food and Beverage | Cash or cash equivalent | $21.35 | General |
| Category: Pediatric Oncology | ||||||
| 05/31/2019 | Hoffmann-La Roche Limited | Non-Covered Product (Drug) | Food and Beverage | In-kind items and services | $73.82 | General |
| Category: None | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 11b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib RXDX-101 in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors, with or without TRK, ROS1, or ALK Fusions | F. Hoffmann-La Roche AG | $1,701 | 4 |
| Open Label Dose Escalation and Expansion Study of Entrectinib RXDX 101 in Children | F. Hoffmann-La Roche AG | $343.46 | 1 |
| A PHASE 11B, OPEN-LABEL, DOSE-ESCALATION AND EXPANSION STUDY OF ENTRECTINIB RXDX-101 IN CHILDREN AND ADOLESCENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS AND PRIMARY CNS TUMORS, WITH OR WITHOUT TRK, ROS1, OR ALK FUSIONS | F. Hoffmann-La Roche AG | $212.68 | 1 |
| A RANDOMIZED, OPEN-LABEL PHASE 1/2 STUDY EVALUATING RAMUCIRUMAB IN PEDIATRIC PATIENTS AND YOUNG ADULTS WITH RELAPSED, RECURRENT, OR REFRACTORY DESMOPLASTIC SMALL ROUND CELL TUMOR | Eli Lilly and Company | $136.00 | 1 |
About Dr. William Cash, MD
Dr. William Cash, MD is a Pediatric Hematology-Oncology healthcare provider based in Atlanta, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/10/2007. The National Provider Identifier (NPI) number assigned to this provider is 1427262286.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. William Cash, MD has received a total of $28,733 in payments from pharmaceutical and medical device companies, with $14,000 received in 2023. These payments were reported across 21 transactions from 6 companies. The most common payment nature is "Honoraria" ($14,000).
Ad
Practice Information
- Specialty Pediatric Hematology-Oncology
- Location Atlanta, GA
- Active Since 05/10/2007
- Last Updated 06/06/2022
- Taxonomy Code 2080P0207X
- Entity Type Individual
- NPI Number 1427262286
Products in Payments
- Sylvant (Drug) $5,000
- Sylvant (Biological) $4,170
- SYLVANT (Drug) $3,000
- ROZLYTREK (Biological) $2,044
- UNITUXIN (Drug) $97.12
- Non-Covered Product (Drug) $73.82
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Hematology-Oncology Doctors in Atlanta
Robert Sidonio, Md, MD
Pediatric Hematology-Oncology — Payments: $898,589
Pediatric Hematology-Oncology $898,589
Shannon Meeks, Md, MD
Pediatric Hematology-Oncology — Payments: $366,833
Pediatric Hematology-Oncology $366,833
Bhavya Doshi, M.d, M.D
Pediatric Hematology-Oncology — Payments: $177,468
Pediatric Hematology-Oncology $177,468
Vivien Sheehan, Md, MD
Pediatric Hematology-Oncology — Payments: $100,331
Pediatric Hematology-Oncology $100,331
Muna Qayed, Md, MD
Pediatric Hematology-Oncology — Payments: $76,871
Pediatric Hematology-Oncology $76,871
Carlton Dampier, Md, MD
Pediatric Hematology-Oncology — Payments: $72,327
Pediatric Hematology-Oncology $72,327